Evidence map›Paper›PMID 32238824›Full record

ArticleScientific reports2020

Hierarchical Cluster and Region of Interest Analyses Based on Mass Spectrometry Imaging of Human Brain Tumours.

Takuya Hiratsuka, Yoshiki Arakawa, Yuka Yajima, Yu Kakimoto, Keisuke Shima, Yuzo Yamazaki, Masahiro Ikegami, Takushi Yamamoto, Hideshi Fujiwake, Koichi Fujimoto and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Topological segmentation of mass spectrometry imaging data.Journal of mass spectrometry and advances in the clinical lab · 2025
    Article
  2. Article
  3. Article
  4. Emerging Computational Methods in Mass Spectrometry Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Takuya HiratsukaDepartment of Drug and Discovery Medicine, Pathology Division, Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan.
Yoshiki ArakawaDepartment of Neural Surgery, Kyoto University Hospital, Kyoto, 606-8507, Japan.
Yuka YajimaDepartment of Microbiology, Muroran Institute of Technology, Muroran, Hokkaido, 050-8585, Japan.
Yu KakimotoDepartment of Forensic Medicine, Graduate School of Medicine, Tokai University School of Medicine, Isehara-Shimokasuya 143, Kanagawa, 259-1193, Japan.
Keisuke ShimaKyoto Applications Development Center, Analytical & Measuring Instruments Division, Shimadzu Corporation, 1 Nishino-kyo-Kuwabara-cho, Kyoto, 604-8511, Japan.
Yuzo YamazakiKyoto Applications Development Center, Analytical & Measuring Instruments Division, Shimadzu Corporation, 1 Nishino-kyo-Kuwabara-cho, Kyoto, 604-8511, Japan.
Masahiro IkegamiKyoto Applications Development Center, Analytical & Measuring Instruments Division, Shimadzu Corporation, 1 Nishino-kyo-Kuwabara-cho, Kyoto, 604-8511, Japan.
Takushi YamamotoKyoto Applications Development Center, Analytical & Measuring Instruments Division, Shimadzu Corporation, 1 Nishino-kyo-Kuwabara-cho, Kyoto, 604-8511, Japan.
Hideshi FujiwakeResearch Center, Shimadzu General Services, Inc., 1 Nishino-kyo-Kuwabara-cho, Kyoto, 604-8511, Japan.
Koichi FujimotoDepartment of Neural Surgery, Kyoto University Hospital, Kyoto, 606-8507, Japan.
Norishige YamadaClinical bioresource centre, Kyoto University Hospital, Kyoto, 606-8507, Japan.
Tatsuaki TsuruyamaDepartment of Drug and Discovery Medicine, Pathology Division, Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan. tsuruyam@kuhp.kyoto-u.ac.jp.
Shimadzu (Japan) · JPKyoto University Hospital · JPKyoto University · JPMuroran Institute of Technology · JPTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imaging mass spectrometry (IMS) has been rarely used to examine specimens of human brain tumours. In the current study, high quality brain tumour samples were selected by tissue observation. Further, IMS analysis was combined with a new hierarchical cluster analysis (IMS-HCA) and region of interest analysis (IMS-ROI). IMS-HCA was successful in creating groups consisting of similar signal distribution images of glial fibrillary acidic protein (GFAP) and related multiple proteins in primary brain tumours. This clustering data suggested the relation of GFAP and these identified proteins in the brain tumorigenesis. Also, high levels of histone proteins, haemoglobin subunit α, tubulins, and GFAP were identified in a metastatic brain tumour using IMS-ROI. Our results show that IMS-HCA and IMS-ROI are promising techniques for identifying biomarkers using brain tumour samples.

Indexed as

Brain ChemistryBiomarkers, TumorBrainBrain NeoplasmsCluster AnalysisHumansPeptidesProteinsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationBiomarkers, TumorPeptidesProteins

Identifiers

PMID32238824
PMCPMC7113320
OpenAlexW3014184572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.